


Product Details

Catalog No.	ATAD00002
INN (International Nonproprietary Name)	Ruplizumab
Purity	>95%

SDS-PAGE image



Concentration	1mg/ml
Formulation	PBS buffer PH7.4
Source	CHO cells
Endotoxin level	Please contact with the lab for this information.
Note	For research use only .

Bioactivity

Description	Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova. Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells and monocytes.
Alternative names	BG-9588, hu5c8
Specificity target name; species	CD40LG[Homo sapiens]
Target information	Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8), which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also, IL17A can stimulate the expression of IL6 and cyclooxygenase-2

(PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).

Furthermore, IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

Species

Humanized

Receptor identification

IgG1-kappa

Chemistry

MV

145448.00 Da

CAS

220651-94-5

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

